Chinese SLE Treatment and Research Group (CSTAR) Registry 2009-2019: Major Clinical Characteristics of Chinese Patients with Systemic Lupus Erythematosus
- PMID: 36467897
- PMCID: PMC9524770
- DOI: 10.2478/rir-2021-0001
Chinese SLE Treatment and Research Group (CSTAR) Registry 2009-2019: Major Clinical Characteristics of Chinese Patients with Systemic Lupus Erythematosus
Abstract
Objective: To describe the overall clinical characteristics of patients from the Chinese SLE Treatment and Research group (CSTAR) registry in the past 10 years.
Methods: CSTAR registry originated as a multicenter, consecutive, and prospective design launched in 2009. The data were collected online from 304 rheumatology centers, which covered 30 provinces in China. All data were generated and uploaded in the clinic directly without secondary collection, including demographic, clinical manifestations, disease activity (SLEDAI-2K) and organ damage evaluation (SLICC Damage Index), and lab test results. Biological samples were preserved for future study. Meanwhile, data cleaning and validation were managed by a professional backstage statistician.
Results: A total of 25,147 SLE patients were registered up to Dec 2019. The mean age of disease onset was 31.2 years with the age of confirmed diagnosis at 32.1 years. The male to female rate was 1:11.9. 4.6% were pediatric patients. The most common clinical presentations at entry were oral ulcer (59.4%), arthritis (55.0%), alopecia (43.22%), skin rash (40.0%), and nephritis (33.5%). The mean SLEDAI score at entry was 4 and 32.6% were in moderate to severely active disease. 66.4% and 37.8% of patients were positive for anti-ds-DNA antibody or low complement level. Additionally, 1.1% of patients were with pulmonary arterial hypertension (PAH). The prevalence rate of cerebrovascular disease was 0.3%. A total of 58.2% of patients were in clinical remission when thery were registered.
Conclusions: The CSTAR registry is the largest ongoing SLE registry in China so far. More than 25,000 SLE patients are registered and nearly 10,000 are in follow-up visits. This registry has provided high-quality data for future studies and will become an infrastructure for domestic and international collaborations.
Keywords: CSTAR; epidemiology; registry; systemic lupus erythematosus.
© 2021 Mengtao Li et al., published by Sciendo.
Conflict of interest statement
Conflict of Interest The authors declare no conflicts of interest.
Similar articles
-
Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus.Lupus. 2013 Oct;22(11):1192-9. doi: 10.1177/0961203313499086. Epub 2013 Aug 20. Lupus. 2013. PMID: 23963101
-
Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus.Lupus. 2014 Sep;23(10):1085-91. doi: 10.1177/0961203314527366. Epub 2014 Mar 20. Lupus. 2014. PMID: 24651670
-
Chinese SLE Treatment and Research group (CSTAR) registry: V. gender impact on Chinese patients with systemic lupus erythematosus.Lupus. 2015 Oct;24(12):1267-75. doi: 10.1177/0961203315585813. Epub 2015 May 13. Lupus. 2015. PMID: 25972364
-
Chinese Systemic Lupus Erythematosus Treatment and Research Group (CSTAR) Registry XI: gender impact on long-term outcomes.Lupus. 2019 Apr;28(5):635-641. doi: 10.1177/0961203319839845. Epub 2019 Apr 2. Lupus. 2019. PMID: 30939980
-
CRDC: a Chinese rheumatology research platform.Clin Rheumatol. 2015 Aug;34(8):1347-52. doi: 10.1007/s10067-015-3003-1. Epub 2015 Jul 11. Clin Rheumatol. 2015. PMID: 26160265 Review.
Cited by
-
Predicting the risk of cardiovascular and cerebrovascular event in systemic lupus erythematosus: a Chinese SLE treatment and research group study XXVI.RMD Open. 2024 Sep 23;10(3):e004425. doi: 10.1136/rmdopen-2024-004425. RMD Open. 2024. PMID: 39313305 Free PMC article.
-
Systematic Review of the Outcomes and Prognostic Factors of Patients With Systemic Lupus Erythematosus-Associated Thrombotic Microangiopathy.Kidney Int Rep. 2025 Apr 16;10(7):2243-2254. doi: 10.1016/j.ekir.2025.04.022. eCollection 2025 Jul. Kidney Int Rep. 2025. PMID: 40677339 Free PMC article.
-
Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes.BMC Med. 2025 Jan 6;23(1):8. doi: 10.1186/s12916-024-03843-9. BMC Med. 2025. PMID: 39757171 Free PMC article.
-
Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus.J Clin Med. 2022 Aug 24;11(17):4955. doi: 10.3390/jcm11174955. J Clin Med. 2022. PMID: 36078885 Free PMC article. Review.
-
Risk prediction of new-onset thrombocytopenia in patients with systemic lupus erythematosus: a multicenter prospective cohort study based on Chinese SLE treatment and research group (CSTAR) registry.Arthritis Res Ther. 2024 Dec 27;26(1):229. doi: 10.1186/s13075-024-03460-0. Arthritis Res Ther. 2024. PMID: 39731190 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous